Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy

Quality of life and patient‐reported toxicities in patients with advanced Merkel cell carcinoma treated with combined nivolumab and ipilimumab with or without stereotactic body radiation therapy

Abstract Background Merkel cell carcinoma is a rare skin cancer associated with poor survival. Based on a previous Phase II trial of adults with advanced Merkel cell carcinoma by Kim and colleagues (2022), there is now a strong rationale for combination therapy (i.e., nivolumab and ipilimumab) to be...

Full description

Saved in:
Bibliographic Details
Main Authors: Aasha I. Hoogland, Andrew S. Brohl, Brent J. Small, Lauren Michael, Evan Wuthrick, Zeynep Eroglu, Dukagjin Blakaj, Claire Verschraegen, Nikhil I. Khushalani, Heather S. L. Jim, Sungjune Kim
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:Cancer Medicine
Subjects:
immune checkpoint inhibitor therapy
Merkel cell carcinoma
patient‐reported outcomes
quality of life
Online Access:https://doi.org/10.1002/cam4.7464
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.7464

Similar Items